Co-amoxiclav Effects on the Structural and Binding Properties of Human Serum Albumin

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2013 Dec 24

PMID 24363734

Citations 2

Authors

Saeed Hesami Takallu

Mostafa Rezaei Tavirani

Shiva Kalantari

Mahrooz Amir Bakhtiarvand

Sayed Mohammad Mahdavi

Affiliations

Soon will be listed here.

Abstract

Human serum albumin (HSA) is the most abundant plasma protein in the human body. HSA plays an important role in drug transport and metabolism. This protein has a high affinity to a very wide range of materials, including metals such as Cu2+ and Zn2+, fatty acids, amino acids and metabolites such as bilirubin and many drug compounds. In this study, we investigated the effects of co-amoxiclav, as a drug which could be carried by this protein, on HSA structure and binding properties via spectroscopy and electrochemistry techniques. Based on this study, it was found that a therapeutic dose of co-amoxiclav as well as doses 4 to 8 folds higher than the therapeutic dose has no considerable effect on the HSA tertiary structure at 37(o)C. However, a dose 2 folds that of the therapeutic dose has a slight effect, but higher doses of the drug has a mild effect in pathological temperature (42(o)C). In addition, charge density of HSA surface is decreased at 42(o)C, compared to 37(o)C. Hence, this finding suggests a reduced role of HSA in regulation of osmotic pressure in the fever conditions, compared to the physiological conditions. Co-amoxiclav reduces the charge surface density of HSA at physiological and pathological temperatures and therefore alters its binding properties, which could be important in drug interference and complications.

Citing Articles

Glucose and fluoxetine induce fine structural change in human serum albumin.

Shahani M, Daneshi-Mehr F, Tadayon R, Hoseinzade Salavati B, Akbar Zadeh-Baghban A, Zamanian A Iran J Pharm Res. 2013; 12(1):185-91.

PMID: 24250587 PMC: 3813215.

Fluoxetine competes with cortisol for binding to human serum albumin.

Rezaei-Tavirani M, Tadayon R, Mortazavi S, Medhet A, Namaki S, Kalantari S Iran J Pharm Res. 2013; 11(1):325-30.

PMID: 24250455 PMC: 3813104.

References

Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E . The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents. 2002; 20(2):119-29. DOI: 10.1016/s0924-8579(02)00126-7. View

Subramanyam R, Gollapudi A, Bonigala P, Chinnaboina M, Amooru D . Betulinic acid binding to human serum albumin: a study of protein conformation and binding affinity. J Photochem Photobiol B. 2008; 94(1):8-12. DOI: 10.1016/j.jphotobiol.2008.09.002. View

Bhattacharya A, Curry S, Franks N . Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J Biol Chem. 2000; 275(49):38731-8. DOI: 10.1074/jbc.M005460200. View

Kratz F . Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132(3):171-83. DOI: 10.1016/j.jconrel.2008.05.010. View

Yin T, Wei W, Yang L, Liu K, Gao X . Kinetics parameter estimation for the binding process of salicylic acid to human serum albumin (HSA) with capacitive sensing technique. J Biochem Biophys Methods. 2007; 70(4):587-93. DOI: 10.1016/j.jbbm.2007.01.009. View

Fiume L, Busi C, Mattioli A, Spinosa G . Targeting of antiviral drugs bound to protein carriers. Crit Rev Ther Drug Carrier Syst. 1988; 4(4):265-84. View

Yapel Jr A . Albumin microspheres: heat and chemical stabilization. Methods Enzymol. 1985; 112:1-18. DOI: 10.1016/s0076-6879(85)12003-3. View

Kragh-Hansen U . Molecular aspects of ligand binding to serum albumin. Pharmacol Rev. 1981; 33(1):17-53. View

Carter D, Ho J . Structure of serum albumin. Adv Protein Chem. 1994; 45:153-203. DOI: 10.1016/s0065-3233(08)60640-3. View

10.

Ueno Y, Mio M, Sato C, Mio K . Single particle conformations of human serum albumin by electron microscopy. J Electron Microsc (Tokyo). 2007; 56(3):103-10. DOI: 10.1093/jmicro/dfm011. View

11.

Ghuman J, Zunszain P, Petitpas I, Bhattacharya A, Otagiri M, Curry S . Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005; 353(1):38-52. DOI: 10.1016/j.jmb.2005.07.075. View

12.

Wang T, Xiang B, Wang Y, Chen C, Dong Y, Fang H . Spectroscopic investigation on the binding of bioactive pyridazinone derivative to human serum albumin and molecular modeling. Colloids Surf B Biointerfaces. 2008; 65(1):113-9. DOI: 10.1016/j.colsurfb.2008.03.008. View

13.

Rezaei Tavirani M, Moghaddamnia S, Ranjbar B, Amani M, Marashi S . Conformational study of human serum albumin in pre-denaturation temperatures by differential scanning calorimetry, circular dichroism and UV spectroscopy. J Biochem Mol Biol. 2006; 39(5):530-6. DOI: 10.5483/bmbrep.2006.39.5.530. View

14.

Sudlow G, Birkett D, Wade D . The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975; 11(6):824-32. View

15.

Fehske K, Muller W, Wollert U . The location of drug binding sites in human serum albumin. Biochem Pharmacol. 1981; 30(7):687-92. DOI: 10.1016/0006-2952(81)90151-9. View

16.

Yang F, Bian C, Zhu L, Zhao G, Huang Z, Huang M . Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol. 2006; 157(2):348-55. DOI: 10.1016/j.jsb.2006.08.015. View

17.

Finch R, Woodhead M . Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs. 1998; 55(1):31-45. DOI: 10.2165/00003495-199855010-00003. View

18.

PETERS Jr T . Serum albumin. Adv Protein Chem. 1985; 37:161-245. DOI: 10.1016/s0065-3233(08)60065-0. View

19.

He X, Carter D . Atomic structure and chemistry of human serum albumin. Nature. 1992; 358(6383):209-15. DOI: 10.1038/358209a0. View